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Different types of DNA damage can initiate phosphorylation-mediated signalling cas-
cades that result in stimulus specific pro- or anti-apoptotic cellular responses. Amongst
its many roles, the NF-κB transcription factor RelA is central to these DNA damage
response pathways. However, we still lack understanding of the co-ordinated signalling
mechanisms that permit different DNA damaging agents to induce distinct cellular out-
comes through RelA. Here, we use label-free quantitative phosphoproteomics to examine
the temporal effects of exposure of U2OS cells to either etoposide (ETO) or hydroxyurea
(HU) by monitoring the phosphorylation status of RelA and its protein binding partners.
Although few stimulus-specific differences were identified in the constituents of phos-
phorylated RelA interactome after exposure to these DNA damaging agents, we observed
subtle, but significant, changes in their phosphorylation states, as a function of both type
and duration of treatment. The DNA double strand break (DSB)-inducing ETO invoked
more rapid, sustained responses than HU, with regulated targets primarily involved in
transcription, cell division and canonical DSB repair. Kinase substrate prediction of ETO-
regulated phosphosites suggest abrogation of CDK and ERK1 signalling, in addition to
the known induction of ATM/ATR. In contrast, HU-induced replicative stress mediated
temporally dynamic regulation, with phosphorylated RelA binding partners having roles in
rRNA/mRNA processing and translational initiation, many of which contained a 14-3-3ε
binding motif, and were putative substrates of the dual specificity kinase CLK1. Our data
thus point to differential regulation of key cellular processes and the involvement of dis-
tinct signalling pathways in modulating DNA damage-specific functions of RelA.
Introduction
RelA, also known as p65, is a key member of the NF-κB family of transcription factors, which serve as
‘master regulators’ of the cellular inflammatory and stress responses, and are key components that
maintain tissue homeostasis and contribute to aging. As part of a functional homo- or hetero-dimer
(preferentially with p50), RelA regulates a diverse set of genes involved in core cellular processes such
as inflammation, proliferation, apoptosis and metastasis [1]. The precise functional roles (the comple-
ment of genes transcribed) of RelA are governed both by its post-translational modification (PTM)
status, and the transcriptional complexes formed, which are themselves regulated in a co-ordinated
fashion through numerous cell signalling pathways [2–4]. PTMs have the potential to regulate many
aspects of NF-κB signalling in response to different stimuli, including nuclear translocation, protein-
protein or protein-DNA interactions, and stability, often working in a combinatorial fashion to regu-
late complex formation and transcriptional output.
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While NF-κB signalling is commonly associated with inflammation and the immune response, these path-
ways also play key roles in the cellular response to DNA stress. Consequently, aberrant NF-κB signalling is
observed in, and often a contributing factor to, many human diseases, including autoimmune disorders,
chronic inflammatory diseases, and cancer [1,5–7]. NF-κB signalling is also central to age-related degenerative
diseases as a result of accumulated age-related DNA damage [8]. The pro-survival effects mediated by NF-κB
in response to specific-types of DNA damage in part explains the cellular resistance to chemotherapy. Hence, a
clear understanding of NF-κB signalling in response to DNA damage is important, not only in the context of
ageing, but also to enhance cancer treatment strategies.
In response to different types of DNA damage, cells invoke specific responses that promote DNA repair,
induce cell cycle arrest, regulate cell death or induce cellular senescence [9,10]. For example, inhibition of DNA
replication using hydroxyurea (HU), which inhibits ribonuclease diphosphate reductase, arrests cells primarily
in S-phase [11–15]. In contrast, agents such as etoposide (ETO), which induces DNA double stranded breaks
(DSBs) by preventing topoisomerase II-mediated DNA re-ligation during replication and cell division, cause
cells to accumulate in the G2/M phase of the cell cycle [16–19]. Whilst activation of NF-κB-responsive genes
following DNA stress has been investigated, the mechanisms of regulating these differential outputs remain
poorly characterised [1,5–7]. Both HU and ETO invoke a DNA damage stress response through ataxia telangi-
ectasia mutated (ATM)-mediated activation of NF-κB, leading to elevated levels of NF-κB targets such as
Survivin and Bcl-xL. However, these two types of DNA damaging agents result in distinct cellular responses in
a variety of tumour-derived cell lines and in primary cells cancer cells, in part due to induction of different
NF-κB gene expression patterns [19–22]; HU mediates a pro-apoptotic response, while an anti-apoptotic
response results following cellular exposure to ETO [22]. Differential involvement of p53 in regulating NF-κB
outputs in response to these different types of DNA damaging agents also plays a role: while the transcriptional
response to HU requires p53 for both early and late NF-κB target gene expression, NF-κB-mediated transcrip-
tion in response to ETO is independent of p53 [22].
The activity of all NF-κB subunits, including RelA, is extensively controlled by a variety of PTMs including
phosphorylation, acetylation, methylation, glycosylation, proline isomerisation, cysteine oxidation and ubiquitina-
tion [23–26]. Of these, phosphorylation accounts for the majority of the well-understood dynamic mechanisms of
regulation, both direct e.g. pSer45 modulation of DNA binding [26], and indirect e.g. pSer276, which controls a
number of other PTMs, including ubquitination and thus RelA stability [2,27,28]. Of relevance here, Thr505
phosphorylation has been shown to mediate pro-apoptotic effects upon cisplatin-induced DNA damage [29,30].
Given the complexity of NF-κB signalling, unravelling the mechanisms by which NF-κB subunits, particularly
RelA, induce differential transcriptional specificity in a context-dependent manner is challenging.
The sensitivity and versatility of mass spectrometry (MS) makes it ideal for the study (identification and quantifi-
cation) of dynamic PTMs and the regulated binding partners of transcription factors and their transcriptional com-
plexes. Here we utilise a label free phosphoproteomics approach to map DNA damage-induced changes in RelA
binding partners and their phosphorylation status, in response to either HU-induced replicative stress, or
ETO-mediated DSB. We find that whilst RelA associated proteins remain largely unchanged as a function of DNA
stress, there are notable changes in the dynamics of phosphorylation of the RelA-interactome as a function of treat-
ment. These findings point towards different signalling pathways directing the formation of specific RelA networks
dependent on the type of DNA damage that likely help direct transcriptional output and thus the cellular response.
Materials and methods
Reagents and antibodies
Unless otherwise stated, general lab reagents were purchased from Sigma Aldrich and were of the highest
quality available. The following primary antibodies were used for immunoblotting at 1/1000 dilution in 5% (w/w)
BSA overnight at 4°C: anti-RelA (sc-372, Santa Cruz), anti-HA (Merck, HA-7), anti phospho-histone H2AX
(#2577, Cell Signalling), anti-PAK4 (#3242, Cell Signaling Technologies), anti-Karyopherin-β1 H-7 (sc-137016,
Santa Cruz). Secondary anti-rabbit IgG (7074S, Cell Signalling Technology) was used at 1/5000 dilution follow-
ing membrane incubation with VeriBlot (1/400 dilution, ab131366 Abcam).
Generation and culture of HA-RelA U2OS cells
The HA-RelA U2OS cell line was generated by transfecting wild-type U2OS cells with the plasmid pRcRSV
HA RelA plasmid, which also expresses the neomycin gene. Cells stably expressing HA tagged RelA were then
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selected by treatment with G418 (600 mg/ml, Melford Chemicals, cat. no. G0175), with pooled populations of
cells used in experiments.
Cell treatment and lysis
U2OS cells expressing HA-RelA (or HA control cells) were cultured in DMEM supplemented with 10% (v/v)
fetal bovine serum, penicillin (100 U/ml), streptomycin (100 U/ml), and L-glutamine (2 mM) at 37°C, 5% CO2.
Once 80% confluence was reached, cells were treated with either 50 mM etoposide (50 mM stock solution in
DMSO) or 2 mM hydroxyurea (100 mM stock solution in DMEM, 5% DMSO), by addition to the culture
media, for the indicated times. Control cells were grown for the maximum time (2 h) in 0.1% (v/v) DMSO.
After removal of the media, cells were washed three times with ice cold PBS. For proteomics analysis, cells were
harvested in 400 ml of lysis buffer (100 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 0.5% (v/v) Triton
X-100, 0.5% (v/v) NP-40, 1× PhosSTOP™ phosphatase inhibitor cocktail tablet (Roche), 1× cOmplete™
Protease Inhibitor Cocktail (Roche), 50 U/ml of benzonase) into 1.5 ml microtubes using a cell scraper. Cells
were then incubated on ice for 120 min to permit cell lysis to occur. Cell lysates were then cleared by centrifu-
gation (16 000×g, 10 min, 4°C) and protein concentration was determined using the Bradford assay. A total
protein amount of 4 mg was set aside for HA-RelA immunoprecipitation. Cell treatment and lysis was per-
formed in triplicate to obtain three independent biological replicates for each treatment condition and control
(untreated) cells for proteomics analysis.
For the RelA co-immunoprecipitation studies, HA-RelA or HA control U2OS cells were lysed in IP lysis
buffer (25 mM Tris pH 8, 0.15 M NaCl, 0.1% (w/v) NP-40, 1 mM EDTA, 1 mM DTT, containing 1×
PhosSTOP™ phosphatase inhibitor cocktail tablet (Roche), and cOmplete™ Protease Inhibitor Cocktail
(Roche)) after treatment with either ETO or HU as above. Protein concentration was determined using a BCA
protein assay kit according to the manufacturer’s instructions (Thermo Scientific).
Immunoprecipitation of HA-RelA for proteomics
Pierce™ Anti-HA Magnetic Beads were washed with 0.05% (v/v) TBST and then with lysis buffer prior to add-
ition of 4 mg cleared cell lysate (at a ratio of beads to protein of 1:2000). Beads and lysate were incubated over-
night using an end-over-end rotor at 4°C. Beads were then collected using a magnetic stand and washed three
times with wash buffer (40 mM Tris-HCl pH 8.0, 0.1% (v/v) NP-40, 1 mM EGTA, 6 mM EDTA, 6 mM DTT,
0.5 M NaCl, 1× PhosSTOP™ phosphatase inhibitor cocktail tablet (Roche), 1× cOmplete™ Protease Inhibitor
Cocktail (Roche)); one time with HPLC grade water and finally, three times with 25 mM ammonium bicarbon-
ate (AMBIC). To recover the immunoprecipitated material, the beads were resuspended in 100 ml of 25 mM
AMBIC to which 6 ml of a 1% (w/v) solution of RapiGest (Waters, UK) in 25 mM AMBIC was added. Samples
were then heated to 80°C for 10 min. Supernatants containing the eluted proteins were recovered using a mag-
netic stand and used for in-solution digestion.
Co-immunoprecipitation of HA-RelA and immunoblotting
Pierce™ protein A/G Magnetic Beads were incubated with anti-HA antibody (sc-7392, Santa Cruz
Biotechnology) in 5% (w/w) BSA for 3 h at 4°C, using 10 ml beads and 1 mg antibody per IP. Beads were
washed three times with IP lysis buffer (500 ml) and incubated overnight using an end-over-end rotor at 4°C.
Beads were then collected using a magnetic stand and washed three times with wash buffer prior to elution of
bound protein in 30 ml of 2× SDS loading buffer for SDS–PAGE and immunoblotting.
In-solution digestion and TiO2-based enrichment of phosphorylated peptides
Samples were digested with trypsin and subjected to TiO2-based phosphopeptide enrichment as previously
described [31]. In brief, disulfide bonds were reduced by addition of DTT to a final concentration of 4 mM
(10 min, 60°C with gentle agitation). Samples were cooled to room temperature and free cysteines alkylated
with 14 mM iodoacetamide (30 min, RT), prior to addition of DTT (to 7 mM final) to quench excess iodoace-
tamide. Samples were digested with trypsin (1:50 trypsin:protein ratio) overnight at 37°C with light agitation
(450 rpm on an Eppendorf thermomixer). Digestion was stopped by the addition of trifluoracetic acid (TFA) to
a final concentration of 0.5% (v/v) and incubated for 45 min at 37°C. RapiGest insoluble hydrolysis products
were removed by centrifugation (13 000×g, 15 min, 4°C). Digested samples were dried by vacuum centrifuga-
tion and resolubilized in TiO2 loading buffer (80% acetonitrile, 5% TFA, 1 M glycolic acid) to achieve a peptide
concentration of 1 mg/ml and sonicated for 10 min. TiO2 beads (50 mg/ml in loading buffer) were mixed at
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1400 rpm (with intermittent vortexing to prevent the beads from pelleting) with the resuspended peptides
(bead:protein ratio of 5:1) for 20 min at RT. TiO2 beads were recovered by centrifugation (2000× g, 1 min) and
washed successively for 10 min (1400 rpm) with 150 ml of loading buffer, 80% acetonitrile 1% TFA, then 10%
acetonitrile, 0.2% TFA. Prior to elution, beads with bound phosphopeptides were dried to completion by
vacuum centrifugation. Bound phosphopeptides were then eluted by addition of 100 ml of 1% (v/v) ammonium
hydroxide and then with 100 ml of 5% (v/v) ammonium hydroxide. Both elutions were combined and dried by
vacuum centrifugation.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis
Phosphopeptide enriched samples were analysed by LC-MS/MS using an Ultimate 3000 RSLC™ nano system
(Thermo Scientific, Hemel Hempstead) coupled to a QExactive HF mass spectrometer (Thermo Scientific). The
samples were loaded onto a trapping column (Thermo Scientific, PepMap100, C18, 300 mm× 5 mm), using
partial loop injection, for seven minutes at a flow rate of 4 ml/min with 0.1% (v/v) FA, and resolved on an ana-
lytical column (Easy-Spray C18 75 mm× 500 mm 2 mm column) using a gradient of 97% A (0.1% formic acid),
3% B (99.9% ACN 0.1% formic acid) to 60% A, 40% B over 80 min at a flow rate of 300 nL/min.
Data-dependent acquisition employed a 60 000 resolution full-scan MS scan (MS1) with AGC set to 3 × 106
ions with a maximum fill time of 100 ms. The 10 most abundant peaks were selected for MS/MS using a 60
000 resolution scan (AGC set to 1 × 105 ions with a maximum fill time of 100 ms) with an ion selection
window of 1.2 m/z and a normalised collision energy of 29. A 20 sec dynamic exclusion window was used to
minimise repeated selection of peptides for MS/MS.
LC-MS/MS data analysis
LC-MS/MS files were aligned in Progenesis QI for Proteomics label-free analysis software. At this stage, no nor-
malisation was performed and an aggregate file containing raw abundances from all the peaks across all runs
was exported from Progenesis. These files were searched against UniProt Human reviewed protein database
(downloaded December 2015; 20 187sequences) using MASCOT (v 2.6) within Proteome Discoverer (v. 1.4;
Thermo Scientific). Parameters were set as follows: MS1 tolerance of 10 ppm, MS2 mass tolerance of 0.01 Da;
enzyme specificity was defined as trypsin with two missed cleavages allowed; Carbamidomethyl Cys was set as
a fixed modification; Met oxidation, and Ser/Thr/Tyr/His phosphorylation were defined as variable modifica-
tions. Data were filtered to a 1% false discovery rate (FDR) on peptide spectrum matches (PSMs) using auto-
matic decoy searching with MASCOT. ptmRS node with Proteome Discoverer was used to determine
phosphosite localization confidence. To match ptmRS scores to Progenesis MASCOT output files, two rounds
of Excel vlookup functions were used: (1) to retrieve scan numbers from the TOP hit per feature number, and
(2) to retrieve ptmRS score using the corresponding scan number.
‘Normalyzer’ software [32] was used to assess the suitability of various types of normalization strategies on
the data. Amongst normalization strategies, VSN-G (group-based variance stabilizing normalisation) performed
well under various quality control metrics indicating a reduction in technical variance. The ‘vsn’ R/
Bioconductor package [33] was then used to normalize log transformed peptide abundance data for the subse-
quent stages of analysis. Pairwise t-test and cross condition ANOVA statistical testing, followed by Benjamini–
Hochberg global correction was subsequently also performed in R for any replicate groups without missing
values. Unless otherwise described, all plots were generated in R.
Network analysis
All proteins with quantified phosphopeptides in two or more (of the three) repeats of any condition were com-
bined for network analysis of RelA-associated proteins. Common contaminants that bind non-specifically in IP
experiments were removed by filtering protein accessions against a CRAPome database (https://www.crapome.
org) [34] of contaminants observed with Streptactin-HA IPs from U2OS cells (CC405, CC406 and CC410). All
proteins not present in the contaminant database were entered into STRING (https://string-db.org, v11.0) to
generate a network of protein associations [35]. The generated network was filtered to contain only high confi-
dence associations (interaction score ≥0.7) with experimental or database evidence only. Proteins with no high
confidence interactions were removed from the network and the remaining nodes were clustered using the
Kmeans algorithm (K = 9). The resulting network was imported into Cytoscape [36] with nodes recoloured,
grouped into the top 9 Kmeans clusters and node shapes for proteins unique to HU or ETO changed to
squares or diamonds respectively. For the top 9 Kmeans clusters, nodes corresponding to proteins with
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differentially regulated phosphopeptides in response to either HU, ETO or both treatments, with respect to the
untreated control, were outlined in red, blue or black respectively.
Functional enrichment analysis
All functional enrichment analysis was performed using the functional annotation tool in DAVID (https://
david.ncifcrf.gov, v6.8) against a background of the human proteome [37,38]. For biological process GO term
pie charts, all significantly enriched (Benjamini adj.P-value≤ 0.05) GO biological process terms, with associated
Benjamini adj.P-values, were summarised using REVIGO [39] then visualised with the CirGO Python package
[40]. Bubble plots including significantly enriched (Benjamini adj.P-value ≤0.05) GO biological process (BP),
molecular function (MF), cellular component (CC) and overrepresented keywords, filtered to remove duplicate
terms, were plotted in R.
Kinase prediction/sequence motif analysis
Kinase-substrate prediction for all differentially regulated (t-test, p≤ 0.05) phosphosites was performed using
NetPhorest [41,42]. Briefly, for all ‘class I’ phosphorylation sites (ptmRS ≥ 0.75) protein identifiers together
with the position of the phosphorylated residue were submitted to NetPhorest using the high-throughput web
interface, with the top scoring prediction for each site reported. Kinase predictions were summarised for all up-
or down-regulated phosphosites with the resulting data plotted in R. For sequence motif analysis, sequence
windows encompassing 7 amino acids either side of the phosphorylated residue were extracted for all phospho-
sites significantly up- or down- regulated (t-test, P≤ 0.05) with respect to the untreated control. Consensus
sequence motifs were generated with iceLogo v1.2 [43] against a background of the precompiled human
Swiss-Prot composition using percent difference as the scoring system and a P-value cut-off of 0.05. The most
confident phosphosite per phosphopeptide was also cross-referenced against data from PeptideAtlas (PA) [64]
(2020 build), and from PhosphoSitePlus (PSP) [65] (11/03/20 build), categorising phosphorylation site confi-
dence based on the number of observations - ‘High’: ≥5 previous observations, very likely true site; ‘Medium’:
2–4 previous observations, likely true site; ‘Low’: 1 previous observation, little support that it is a true site; PA
only – ‘Not phosphorylated’: frequently (>5) observed to be not phosphorylated, never observed as phosphory-
lated; ‘Other’ – no confident evidence in any category. Observations in PA were counted with a threshold of
>0.95 PTM Prophet probability for positive evidence, and ≤0.19 for evidence of not being phosphorylated.
Results
Selection of DNA damage timepoints
To identify changes in the phosphorylation status of RelA and its protein binding partners in response to dif-
ferent types of DNA damage, we first examined the kinetics of DNA damage after treatment with either the
DSB inducer ETO, or the replicative stress inducer HU in the HA-RelA U2OS cell line. Using gamma-H2AX
as a marker [44,45], we observed rapid DNA damage (within 30 min) following treatment with either ETO or
HU (Figure 1; Supplementary Fig. S1). Gamma-H2AX levels peaked faster with ETO than HU, but sustained
(and maximal) levels were observed with both agents following ∼2 h of continuous treatment. A time-course of
the effect of these different DNA damaging agents on the RelA phosphorylation interactome was therefore eval-
uated by treatment of the HA-RelA U2OS cells with either ETO or HU for 0, 30, 60 or 120 min prior to immu-
noprecipitation (IP) of the HA-tagged RelA. Immunoprecipitated proteins were subject to titanium dioxide
(TiO2)-based phosphopeptide enrichment prior to LC-MS/MS with label-free peptide quantification (Figure 1).
Network of RelA-associated proteins
Using the identified (phospho)peptides as proxy for protein identifications, the list of RelA bound proteins
under all conditions was filtered against a ‘CRAPome’ database of contaminants commonly observed in
Streptactin-HA IPs from U2OS cells (CC405, CC406 and CC410), which provided the closest match to the
experimental workflow described here. Phosphopeptide quantification data was normalised and subjected to
ANOVA testing across all conditions, and individual t-tests across all pairs of conditions. Using this list, the
temporal effect of treatment with either ETO or HU on RelA bound phosphoproteins was evaluated for all
those proteins quantified in at least 2 biological replicates, under a given condition.
To generate a network of high confidence interactors, the remaining 815 RelA-associated proteins combined
across all conditions (Supplementary Table S1) were inputted into STRING (v11.0) [35] using experimental
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and database sources only, and clustered using the Kmeans algorithm (k = 9). Twelve of these proteins failed to
yield high confidence interactions and therefore were filtered out of subsequent datasets (Figure 2). Gene
Ontology (GO) enrichment analysis of biological function for these 803 proteins within the top 9 network clus-
ters confirmed association of RelA with a number of IκB kinase/NF-κB signalling proteins (Figure 2A), includ-
ing RelB, c-Rel, p105/p50, p100/p52, IκBα, IκBβ, and the DNA damage response (Figure 2B). Clusters of
proteins across a number of core cellular processes were also identified in the RelA interactome, including key
proteins involved in cell division, transcriptional regulation, mRNA/rRNA processing and MAPK/ERK/VEGF
signalling (Figure 2A–H). Amongst these interactions partners, we also confirmed observation of a number of
known RelA binding proteins, including e.g. replication factor C (RFC1), p300, SP1 and HDAC6 [46–49].
To determine the temporal response in the RelA interactome of phosphorylated proteins to the different
DNA damaging agents, we evaluated those quantified proteins exhibiting a statistically significant (t-test, P≤
0.05) change in response to time-dependent treatment with ETO or HU, in comparison to control (DMSO
treated) cells. Interestingly, the constituents of the RelA interactome changed very little in response to DNA
damage, with the vast majority of the phosphoproteins identified being observed before and after exposure to
either ETO or HU (round nodes, Figure 2). Of the 803 protein binding partners with high confidence interac-
tors, only 7 were unique to ETO (diamond nodes, Figure 2; Table 1), while 8 were specific to HU (square
nodes, Figure 2; Table 1).
Of the 7 ETO-specific proteins identified in this network, three are essential components of the ERK/MAPK
signalling pathway: the protein kinases ERK1 and PAK, and DUSP9, a dual specificity phosphatase that
Figure 1. Workflow for evaluation of DNA damage response of HA-RelA U2OS cells with either Etoposide (ETO) or
Hydroxyurea (HU).
(A) HA-RelA U2OS cells were treated with either 0.1% DMSO (control), ETO (50 mM) or HU (2 mM) for the times indicated to
induce DNA damage. (B) Following treatment with either ETO or HU, HA-RelA U2OS cell lysates were immunoblotted with
antibodies against either γH2AX as a marker of DNA damage, or RelA/p65. (C) Workflow for evaluation of the phosphorylated
RelA interactome. Cells were treated as in (A), and RelA-bound proteins immunoprecipitated with an anti-HA antibody. Proteins
were subjected to tryptic digestion and TiO2-based phosphopeptide enrichment. (D) Peptides were analysed by LC-MS/MS
using a QExactive HF and subjected to label-free quantification following appropriate normalisation.
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preferentially targets the MAPK/ERK family. A fourth member of this ETO-specific cohort, AAED1 (which has
no known common confident interactors and is therefore not represented in Figure 2), is also reported to posi-
tively regulate the ERK/MAPK (and AKT1) pathway, ultimately leading to upregulation of hypoxia-inducible
factor (HIF)-1α and enhanced glycolysis [50]. In contrast, the 8 HU-specific proteins exhibited diverse bio-
logical functions, with only one of these proteins, nucleoprotein TPR, falling into one of the top 8 network
clusters (Figure 2A).
Figure 2. Network map of RelA interacting phosphoproteins.
Proteins from phosphopeptides quantified following HA-RelA immunoprecipitation in control (0.1% DMSO), ETO (50 mM) or HU
(2 mM) treated U2OS cells were evaluated with STRING (v11.0) [35] for prior experimental evidence of interaction. Kmeans
clustering was used to identify the top 9 enriched GO clusters of biological function and plotted using Cytoscape [36]. The
shape of the nodes represent the conditions under which they was identified: round nodes represents proteins identified
across all conditions; diamond nodes indicate proteins unique to ETO treatment; square nodes indicate proteins unique to HU
treatment. (A) red nodes represent those proteins mapped to IKK/NF-κB signalling; (B) dark green nodes represent those
proteins mapped to DNA damage response/DNA repair; (C) blue nodes represent those proteins mapped to repression of gene
expression; (D) yellow nodes represent those proteins mapped to transcriptional regulation; (E) pink nodes represent those
proteins mapped to mRNA processing/splicing; (F) violet nodes represent those proteins mapped to ribosome biogenesis/
rRNA processing; (G) light green nodes represent those proteins mapped to cell division/mitosis; (H) purple nodes represent
those proteins mapped to MAPK/VEGF signalling. Proteins outside of these eight enriched clusters have nodes in grey. The
outline colour of the nodes within the eight clusters shows proteins with differentially regulated phosphopeptides following
treatment with either ETO (blue), HU (red), or both (black).
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In support of the RelA protein networks defined in these proteomics experiments, we confirmed PAK4 as a
novel ETO-regulated RelA binding partner by co-immunoprecipitation, with PAK4 binding occurring max-
imally in these experiments after 60 min treatment with ETO (Figure 3). No discernible increase in PAK4
binding was observed in response to cellular treatment with HU.
Also highlighted in the nodes of the top 8 network clusters are the proteins for which we identified statistic-
ally significantly differentially regulated phosphopeptides (t-test, P≤ 0.05) in response to treatment with either
ETO or HU (or both) with respect to the (DMSO treated) control cells (Figure 2A–H; Supplementary
Table S3). Interestingly, the proteins with differentially regulated phosphopeptides following either ETO or HU
treatment are largely distinct between the two types of DNA damaging agents, and are interspersed across the
network clusters rather than being specific to certain functional biological groups (Supplementary
Figure S2-gifs). These data thus suggest that whilst there was relatively little change in the RelA-associated
Table 1 DNA damage specific RelA binding partners
Treatment UniProt ID Protein name
Etoposide Q86U06 Probable RNA-binding protein 23
O96013 Serine/threonine-protein kinase PAK 4
P27361 Mitogen-activated protein kinase 3
Q8WYH8 Inhibitor of growth protein 5
Q9BXP5 Serrate RNA effector molecule homolog
Q7RTV5 Peroxiredoxin-like 2C
Q99956 Dual specificity protein phosphatase 9
Hydroxyurea Q9BY44 Eukaryotic translation initiation factor 2A
Q8N3F8 MICAL-like protein 1
Q4G0J3 La-related protein 7
O94979 Protein transport protein Sec31A
Q12931 Heat shock protein 75 kDa, mitochondrial
E9PRG8 Uncharacterized protein C11orf98
O75113 NEDD4-binding protein 1
P12270 Nucleoprotein TPR
Proteins identified as binding HA-RelA only in the presence of either etoposide or
hydroxyurea are listed.
Figure 3. Co-immunoprecipitation of PAK4 with RelA increases following cellular treatment with etoposide.
HA-RelA or HA control U2OS cells were treated with either ETO (50 mM) or HU (2 mM) for the times indicated to induce DNA damage. Total cell
extracts (inputs, left) or HA-RelA immunoprecipitated samples (αHA IP, right) were then analysed by western blot with antibodies against either
PAK4, RelA or KPNB1 (as a loading control). Data are representative of three independent experiments.
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phosphoproteins as a function of DNA damage, the phosphorylation states of those associated proteins were
dependent on both the type and duration of the induced DNA damage response.
Rela is minimally differentially phosphorylated in U2OS cells in response to
ETO or HU treatment
Looking specifically at RelA, we observed good sequence coverage of the N-terminal region (>70%; 46% overall;
Supplementary Fig. S3), allowing us to quantify most of the known phosphorylation sites in the N-terminal half
of the protein including; Ser42, Ser45, Ser131, Ser203/Ser205, Ser238, Ser240 and S316. Two novel phosphoryl-
ation sites at Thr54 and Ser169 were also observed (Supplementary Fig. S3). No phosphorylation sites were confi-
dently identified in the C-terminus of RelA containing the transactivation domains (TAs), in part due to the
limited ability to generate suitable tryptic peptides for analysis (as documented previously [26]). Although phos-
phopeptides covering the extreme C-terminus (from residue 503 and including the known sites of phosphoryl-
ation at T505, S529 and S536) were observed, the site of phosphorylation could not be unambiguously defined.
Overall, the changes observed in RelA phosphorylation in response to DNA damage under these conditions
were very limited. Only Ser131 was statistically significantly regulated by both the DSB-inducing ETO and HU:
pSer131 increased marginally by 1.03-fold (with respect to the DMSO-treated control) at 120 min (P-value =
0.047) in response to ETO, responding more rapidly to HU, increasing 1.05 fold by 30 min (P-value = 0.046),
decreasing slightly (although not statistically) by 60 min, and returning to baseline levels by 120 min. We have
previously shown that this site is also responsive to TNFα treatment of U2OS cells, and phosphorylated in vitro
by IKKβ, in a manner that is significantly enhanced in the presence of the RelA dimerization partner, p50, and
reduced in the presence of IκBα [26]. In contrast, Ser45, a phosphorylation site that we previously demon-
strated plays a critical role in reducing the ability of RelA to bind to DNA (alongside Ser42, which was not
observed in the HU-treated cells) [26], was reduced by 1.1 fold (P-value <0.01) 60 min after cellular treatment
with HU, suggesting an HU-mediated regulation of RelA transcription, in part through Ser45 phosphorylation
(Supplementary Fig. S3).
ETO and HU induced different phosphorylation dynamics in the RelA network
Of the 696 proteins identified in the RelA network in the presence of ETO, 184 exhibited ETO-dependent
changes in phosphorylation status, with a total of 312 phosphopeptides exhibiting a statistically significant
change. GO term analysis of biological processes of these 184 proteins revealed enrichment primarily of pro-
teins involved in transcription (P < 0.001), RNA processing (P < 0.001), cell division (P < 0.001) and, unsurpris-
ingly, the DNA damage response (P < 0.001) (Figure 4A). Slightly fewer changes arose in response to HU, with
235 phosphopeptides from 157 proteins exhibiting a statistically significantly change compared to control
(Figure 4B), those primarily being involved in translation (P < 0.001) and rRNA processing (P < 0.001).
Interestingly, only 37 of the proteins exhibiting dynamic changes in response to treatment were common
between the two types of DNA damaging agent, indicating significant differences in the mechanisms whereby
RelA mediates the outputs from these two DNA damaging agents (Figure 4C). For each of the phosphorylation
sites identified in these experiments, we also determined if they had been observed previously in either
PhosphositePlus (PSP), or Peptide Atlas (PA), categorising our quantified phosphosites based on the number
of prior observations (Supplementary Tables S2, S3). Of the ∼3100 unique phosphorylation sites identified in
these studies, ∼70% have been previously observed at medium or high confidence in PSP, having been observed
at least twice previously. Of those phosphorylation sites that were dynamically regulated (with statistical signifi-
cance) in response to cellular treatment with either of these DNA damage agents, 86% and 93% (for ETO and
HU respectively) have been reported previously.
We next evaluated the temporal dynamics of these phosphorylation changes as a function of treatment type
(Figure 4D). Intriguingly, ETO and HU induced very different dynamics in phosphosite regulation. Indeed,
approximately one-quarter (∼70 phosphopeptides) of the ETO-regulated phosphopeptides, were responsive
within 60 min of treatment, with the change in phosphorylation status being maintained over the duration of
the 120 min experiment (Figure 4D,E). In contrast, only 8% (∼20 phosphopeptides) of HU-dependent phos-
phorylation changes occurred within the first 60 min and were then sustained for the duration (Figure 4D,F).
Overall, HU-mediated phosphorylation changes were much more dynamic, with 39% of the phosphopeptides
quantified in these experiments significantly regulated (being observed at either increased, or reduced levels),
before reverting back, either to control levels, or in some instances, in the opposite direction. Just over half of
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those phosphopeptides that were differentially regulated by either ETO or HU did not exhibit a statistically sig-
nificant change until after more than 60 min of continuous treatment, i.e. they were late responders that were







Figure 4. Etoposide and Hydroxyurea induced different phosphorylation dynamics in the RelA network.
GO term biological process enrichment was examined for all phosphopeptides exhibiting a statistically significant change in response to either (A)
etoposide (ETO) or (B) hydroxyurea (HU). (C) Overlap of those proteins with significant change in phosphopeptide abundance at one or more time
points with ETO or HU. (D) Distribution of phosphopeptide changes between sustained, dynamic and late responders for ETO vs HU treatment,
where ‘Late Responders’ indicates a change at 120 min only, ‘Sustained’ indicates a change at 30 or 60 min which is sustained throughout, and
‘Dynamic’ indicates a change at 30 or 60 min which is reversed. (E and F) Heatmaps of the fold change in phosphopeptide levels following
treatment with either ETO (E) or HU (F) at 30, 60 or 120 min relative to control levels. Hierarchical row clustering was performed on the log2 fold
changes.
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Phosphorylation of RelA-associated proteins in response to etoposide
Of the 312 phosphopeptides that were differentially regulated by ETO (with respect to the untreated control
(P≤ 0.05)) across all time-points, 151 increased in abundance, while 159 were down-regulated (Supplementary
Table S2). Only two phosphorylation sites exhibited significant temporal dynamics (with levels being signifi-
cantly elevated or decreased at sequential time-points), although the selective nature of the timing at which
these measurements were made could be masking additional dynamics. Overall, the relative fold change in
phosphopeptide abundance (up- or down-) was relatively small, with the greatest statistically significant fold
change being ∼1.4 (Figure 5A–C; Supplementary Table S2). 14 phosphopeptides were quantified in all three
biological replicates for a given ETO condition but absent in control cell lysates. As the fold-change in relative
abundance could thus not be defined for these phosphopeptides, they are not represented on the volcano plots
in Figure 5A.
In-depth functional enrichment analysis of proteins that were either up- or down-regulated following ETO
exposure revealed some key differences in terms of the biological functions that were regulated (Figure 5D).
RelA-associated proteins with an ETO-mediated reduction in phosphopeptide levels showed significant enrich-
ment for GO terms including mitosis, chromatin regulation (including H4-K16 acetylation), transcriptional
regulation and DNA damage repair (Figure 5D). pSer780 on MDC1, the Mediator of DNA damage checkpoint
protein 1, exhibited the greatest down-regulation of all phosphosites in response to ETO across the time-points
investigated (1.3-fold down; P = 1.95 × 10−04) (Supplementary Table S2, Figure 5A–C). This phosphorylation
site has previously been identified has being induced in response to ionising radiation (IR) [51] and ultraviolet
(UV) radiation [52], both of which induce DSB, although the physiological function of this phosphorylation
site has not yet been defined. We show here that the proportion of Ser780 phosphorylated MDC1 that contri-
butes to the RelA interactome decreases in response to ETO, suggesting that DNA-damage induced pSer780
may serve to disrupt the interaction of MDC1 with RelA transcriptional complexes.
It is interesting to note that many more phosphopeptides were significantly upregulated than were decreased
in the RelA interactome in response to ETO, particularly in the later time points. Transcriptional regulation
and DNA damage repair were also among the GO terms enriched for those proteins with up-regulated phos-
phorylation sites. However, there was only an ∼8% overlap in common proteins with differentially regulated
(up or down in response to ETO) phosphopeptides (Supplementary Table S2), suggesting co-ordinated regula-
tion of these key processes largely through different protein effectors rather than differential phosphorylation-
mediated regulation of the same proteins. Also among the GO terms enriched in the list of proteins with
up-regulated phosphopeptides in response to ETO were mRNA processing, ATP binding, transcription core-
pressor functionality and type I interferon production, including the NF-κB signalling proteins (RelA
(pSer131), NFKB1 (p105/p50) (pSer923;Ser927) and NFKB2 (p100/p52) (pSer858, pTyr868 and pSer870),
with pSer619 on the RNA helicase DDX41 and pSer3205 on the DNA-dependent protein kinase PRKDC
(Figure 5D). Multiple phosphopeptides from the transcription factor zinc finger protein 281 (ZNF281/GZP1/
ZBP99), containing pSer395 (P = 2.1 × 10−02), pSer620 (P = 1.1 × 10−04), pSer785 (P = 1.9 × 10−06) and pSer807
(P = 1.7 × 10−03), were significantly upregulated across all time points (between 1.2–1.4-fold) in the RelA inter-
actome in response to ETO, but not in response to HU. ZNF281 has recently been reported to be recruited to
DSBs, following interaction of its zinc finger domain with XXCR4 [53], where is plays an important role in
non-homologous end-joining upon DNA damage, and consequently the maintenance of cell viability.
Supporting our observations of increased phosphopeptides in response to DSB, these authors also reported a
slight reduction in the recruitment of a non-phosphorylatable S785A/S807A ZNF281mutant to sites of DNA
damage. Based on our data, we would suggest that phosphorylation of ZNF281 on Ser395 and Ser620 may also
be required for its optimal recruitment to DNA lesions and subsequent DNA repair.
In an attempt to understand the signalling pathways and possible kinase-substrate relationships feeding into
the ETO-dependent changes in phosphorylation of the RelA-binding partners, the ‘class I’ localized phospho-
sites (ptmRS≥ 0.75) with P-value ≤0.05 were used as input sequences for the NetPhorest kinase-substrate pre-
diction algorithm [34,35] (Figure 5E). Of the 117 down-regulated and 107 up-regulated phosphorylation sites
that passed the above thresholds, NetPhorest gave kinase-substrate predictions for 37 and 32 sites respectively.
Among the down-regulated sites, the CDKs had the highest number of predicted substrates (14, 38%), account-
ing at least partially, for the notable enrichment across all the ETO down-regulated phosphorylation sites for
Pro in the +1 position with respect to the site of phosphorylation [54] (Figure 5F). Although CDK1 was
defined by NetPhorest as the most likely regulator of these substrates (Supplementary Table S2 and Figure 5), it
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 543













Figure 5. Etoposide-mediated phosphopeptides changes in the RelA network.
Volcano plots showing fold changes in phosphopeptide abundance following Bayesian statistical analysis to evaluate significant differences as a
function of (A) 30 min, (B) 60 min or (C) 120 min treatment with ETO. Log2-fold change are presented as a function of the −Log2 p-value;
differentially down-regulated (red) or up-regulated (blue) phosphopeptides with a P-value ≤0.05 are highlighted. Select data points are annotated
with their protein accession number and site of phosphorylation. Phosphopeptides observed upon ETO treatment, but not in the control extracts are
not reported here. (D) GO term enrichment analysis using DAVID of proteins with significantly regulated phosphopeptides in response to ETO (all
time points) relative to control. Phosphopeptides with a Benjamini–Hochberg adjusted P-value ≤0.05 are labelled. BP, biological process (green);
CC, cellular compartment (yellow); MF, molecular function (purple); UP, UniProt keyword (pink). (E) NetPhorest kinase-substrate prediction for
significantly down- (red) or up-regulated (blue) phosphosites. IceLogo sequence analysis of (F) down-regulated or (G) up-regulated phosphosites.
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should be noted that the overlapping substrate specificity of CDK1/2/3/5 means that it is not possible to differ-
entiate substrates of the different CDK family members. The identification of four predicted substrates for
ERK1 (MAPK3), which is also a Pro-directed protein kinase [55], likely also contributes to the identified
sequence motif, and correlates with our observations of this enzyme, and importantly, a cognate phosphatase,
DUSP9, in the RelA network under these conditions.
IceLogo sequence analysis of the ETO up-regulated phosphosites showed significant enrichment for Gln
(and to a lesser extent Pro) at the +1 position with respect to the site of phosphorylation (Figure 5G). Positions
+2 to +5 also exhibited a strong preference for acidic residues (Asp/Glu), consistent with observation of 14 pre-
dicted substrates for casein kinase II alpha (CK2α2) in the NetPhorest output (Figure 5E). Perhaps not surpris-
ingly given its somewhat promiscuous substrate repertoire, and an involvement in diverse cellular processes
(including regulation of numerous transcription factors such as NF-κB), CK2α2 was also predicted as the regu-
latory enzyme for a number of the significantly down-regulated phosphorylation sites. The striking observation
of Gln at +1 in 36 of the up-regulated phosphorylation sites (Figure 5G) is in agreement with previous reports
of ATM/ATR-dependent regulation of the RelA NF-κB pathway in response to DSB (albeit following cellular
exposure to TNFα rather than etoposide) [56]. ATM/ATR kinases are well known to preferentially phosphoryl-
ate Ser/Thr residues followed by a Gln, with substrates often containing several closely spaced SQ/TQ motifs in
regions termed SQ/TQ cluster domains (SCDs) [57]. Whilst just 7 of the 36 SQ motif-containing sequences
were predicted by NetPhorest to be ATM sites, it is possible that many more of the differentially regulated
phosphosites that match to this consensus are potential ATM/ATR substrates, given the limitations of predic-
tion software. While phosphorylation at any given site can be induced by more than one protein kinase in
cells, the NetPhorest algorithm is best used as a guide and will only assign a single potential enzyme, based on
the best fit, and is therefore not fully representative of cellular possibilities.
Phosphorylation of RelA-associated proteins in response to hydroxyurea
Upon HU treatment, 235 phosphopeptides from 157 proteins in the RelA interactome network were signifi-
cantly differentially regulated with respect to the DMSO treated control (P≤ 0.05; Figure 6A–C). Of those, 121
phosphopeptides increased in abundance, while levels reduced for 109 phosphopeptides. Among the phosphor-
ylation sites exhibiting a dynamic response over the time-course of HU treatment, five showed a bi-directional
response, increasing in some time points, but reducing in others, with respect to control levels (Supplementary
Table S3). Only seven phosphopeptides were quantified in all three biological replicates at a single HU time
point that were not observed in the control cell extracts.
RelA-associated proteins with statistically significantly reduced phosphopeptide levels in response to
HU-mediated DNA damage were notably enriched for GO terms encompassing ribosome biogenesis, mRNA
processing and translation (Figure 6D). Notably, whilst translation was enriched among the proteins effected by
HU treatment there was no significant enrichment for proteins involved in translation with ETO. In contrast,
elevated phosphopeptide levels were observed for processes such as chromatin regulation and chromosomal
rearrangement, and to a lesser extent, transcriptional regulation and mitosis (Figure 6D). Whilst transcriptional
regulation was among the GO terms enriched in response to HU, it was only marginally enriched, and with a
much lower significance than our observations with ETO, suggestion a more much limited effect on transcrip-
tional regulation with HU than with ETO (Figure 5D, Figure 6D).
In agreement with the γH2Ax immunoblotting data (Figure 1B) which indicated a slower cellular response
to HU than ETO (see the heatmaps in Figure 4F), very few significant changes in phosphopeptide abundance
were observed 30 min after treatment with HU (Figure 6A). Interestingly, the NFKB2 (p100) peptide phos-
phorylated on either Ser858/Thr859 (site ambiguous) exhibited the greatest increase of any phosphopeptides at
this time point, with a 1.4-fold change (Supplementary Table S3; being observed in two charge states)
(Figure 6B). This increase in HU-mediated phosphorylation is supported by additional quantification of a
smaller peptide in which the site of phosphorylation was defined as Ser858 (Supplementary Table S3), a site
which was also significantly upregulated following exposure to ETO (Supplementary Table S2). Of note, these
peptides (and others in the C-terminus of p100 that are differentially regulated in response to treatment) are
specific to p100, rather than the transcriptionally active p52 cleavage product, suggesting DNA damage-
mediated regulation of either p100 processing, or its ability to bind (directly or indirectly) to RelA.
The second most differentially elevated phosphopeptide after 30 (and 60) min treatment with HU was the
doubly phosphorylated pThr185/pTyr187-containing peptide from ERK2. This phosphopeptide lies in the
kinase activation loop and phosphorylation of both of these sites is required for catalytic activation of ERK2
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Figure 6. Hydroxyurea-mediated phosphopeptides changes in the RelA network.
Volcano plots showing fold changes in phosphopeptide abundance following Bayesian statistical analysis to evaluate significant differences as a
function of (A) 30 min, (B) 60 min or (C) 120 min treatment with HU. Log2-fold change are presented as a function of the −Log2 p-value; differentially
down-regulated (red) or up-regulated (blue) phosphopeptides with a P-value ≤0.05 are highlighted. Select data points are annotated with their
protein accession number and site of phosphorylation. Phosphopeptides observed upon HU treatment, but not in the control extracts are not
reported here. (D) GO term enrichment analysis using DAVID of proteins with significantly regulated phosphopeptides in response to HU (all time
points) relative to control. Phosphopeptides with a Benjamini–Hochberg adjusted P-value ≤0.05 are labelled. BP, biological process (green); CC,
cellular compartment (yellow); MF, molecular function (purple); UP, UniProt keyword (pink). (E) NetPhorest kinase-substrate prediction for
significantly down- (red) or up-regulated (blue) phosphosites. IceLogo sequence analysis of (F) down-regulated or (G) up-regulated phosphosites.
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[58,59]. An early consequence of HU treatment on the RelA interactome network thus appears to be activation
of bound ERK2, which contrasts with our observations with ETO, where there were no significant changes
induced in MAPK1/ERK2 phosphopeptides. These findings are curious in light of the fact that the C-terminal
region of p100 is reported to bind to inactive ERK2, thereby preventing its phosphorylation and nuclear trans-
location. The fact that we observe increased phosphorylation of ERK2 alongside phosphorylation in the
C-terminal ‘death domain’ of p100 may suggest a role for these p100 phosphorylation sites in regulating its
ability to interact with ERK2 [60].
Nibrin, a member of the MRN complex which plays a critical role in DSB repair and cell cycle checkpoint
control, also exhibited elevated Ser343 phosphorylation by 30 min HU treatment. Interestingly, the pSer343 site
observed falls within an SQ motif which has previously been shown to be phosphorylated by ATM in response
to IR, and is believed to play a role in intra-S phase checkpoint activation [61,62] (Figure 6A,E). This same
phosphorylation site was also rapidly elevated in response to ETO (Figure 5B), confirming its apparent involve-
ment in a generic ATM-mediated DNA damage response [61,62]. By 60 min, we also observed reduced levels
of pSer142 on DPF2 (Zinc finger protein ubi-d4), a known regulator of the non-canonical NF-κB pathway
[63], and pThr220/221 (site ambiguous) on the RelA binding partner RPS3 (40S ribosomal protein S3), both of
which have previously been reported to be elevated in HEK293 cells following 3 h UV exposure [52]. Although
binding of RSP3 to RelA is thought to enhance its ability to bind DNA in vitro [64], RSP3 functions as a nega-
tive regulator of H2O2-mediated DNA repair [65]. It is possible therefore that pThr220/221 on RPS3, and
pSer142 on DPF2, serve to modulate the RelA transcriptional complexes and/or the consensus promoter
regions for NF-κB binding, that are required for DNA repair in response to HU.
Using NetPhorest [41,42], we were able to predict possible kinase-substrate relationships for 46% (77 out of
167) of the ‘class I’ phosphosites (ptmRS≥ 0.75) that were regulated in response to HU (Figure 6E). CK2α2 was
predicted as the kinase responsible for the vast majority (27 out of 43) of the phosphosites reduced in response
to HU, based on the prevalence of acidic residues C-terminal to the site of phosphorylation (in particular at +3)
clearly evident in the sequence analysis (Figure 6F). Consequently, HU might have significant effects on CK2α2
(or other acidophilic kinases) that feed into the RelA-mediated DNA damage response. Prevalent among both
up- and down-regulated phosphosites were predicted substrates of the cyclin-dependent kinases (CDK1/2/3/5
group) which, together with the prediction of substrates for ERK1 (MAPK3) and p38α (MAPK14), contributes
to the enrichment of Pro at the +1 position in both the HU up- and down-regulated phosphosites (Figures 5G,
6F). Also among the up-regulated phosphopeptides are a number of predicted ATM substrates which, whilst
only representing a small proportion of the total number of HU-regulated phosphosites, corresponds with the
small enrichment for Gln in the +1 position among the up-regulated phosphosites. (Figure 6E,G).
Comparing the putative kinase-mediated regulation of substrates for those differentially regulated phospho-
peptides in the RelA interactome in response to the two different types of DNA damaging agents revealed
some interesting observations: although ATM-predicted substrates were enhanced with both ETO and HU,
over twice as many putative substrates were elevated with ETO. Predicted substrates for CK2α2 are prevalent in
the differentially regulated (both up- and down-) phosphosites under both conditions, although HU induces a
far greater reduction in levels of putative CK2α2 substrates than ETO. In contrast, putative substrates for the
dual specificity protein kinase CLK1, which has a role in regulating alternative splicing, are notably elevated in
response to HU (Figure 6E), but not particularly with ETO (Figure 5E). Interestingly, binding sites for 14-3-3ε,
which generally conform to the RXXpS/TXP consensus, were elevated under both conditions, but particularly
in response to HU. 14-3-3 proteins are known to be involved in the cellular response to DNA damage; 14-3-3ε
in particular modulates NF-κB signalling in part by virtue of its ability to bind phosphorylated TAK1 (and its
cognate phosphatase PPM1B), and thereby regulate its anti-apoptotic capabilities [66,67]. In response to DNA
damage stress, this manifests as inhibition of the anti-apoptotic activity of TAK1, promoting an apoptotic
phenotype that is enhanced by the 14-3-3ε-mediated disruption of DP-2 from the E2F transcriptional complex
[68]. The fact that we observe elevated putative 14-3-3ε binding sites following HU treatment (but significantly
less so with ETO), is in agreement with the pro-apoptotic response of HU-treated cells. Consequently, we
hypothesise that the ability of components of the RelA interactome to bind 14-3-3ε may be a driving factor in
achieving the expected cell death/survival phenotype in response to these two DNA damaging agents.
Discussion
Protein phosphorylation is a key reversible, dynamic PTM that rapidly governs protein complex formation, par-
ticularly of transcription factor complexes, thereby coupling extracellular stressors with compensatory
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transcriptional output. To understand the role of phosphorylation in regulating the RelA transcriptional network
in response to different types of DNA damage, we used quantitative phosphoproteomics to explore the dynamics
of the phosphorylated RelA interactome in response to either ETO or HU. Evaluating the RelA network under
these conditions is pertinent, given the central role of this transcription factor in directing the cellular response
towards either senescence or apoptosis. Exposure of U2OS cells to either ETO or HU had very limited effect on
the phosphorylated RelA interactome; only 246 of the 815 RelA interacting phosphoproteins that we identified
in total changed upon treatment. Of these, less than 1% were specific to the type of DNA stress, with 7 or 8
unique proteins (respectively) being identified in the RelA network following exposure of U2OS cells to either
the DSB-inducing ETO or to HU. However, although there was little change in the make-up of this network,
there was evidence of subtle, but significant, changes in the phosphorylation states of the RelA bound proteins
as a function of both the type of and duration of the DNA damaging agent used. Not only did the anti-
apoptotic agent ETO invoke a more rapid cellular response than HU, both in terms of maximal H2AX levels
(Figure 1B), and quantifiable changes in phosphopeptide levels (Figs. 4–6; Supplementary Tables S2, S3), but
interestingly this study pointed to the differential regulation of key cellular processes and the involvement of
unique signalling pathways in modulating the treatment-specific functions of RelA.
Examination of the RelA network hub (the bait) revealed two novel phosphorylation events amongst the RelA
phosphopeptides that we were able to identify and quantify in this trypsin-based peptide analysis: Thr54 and
Ser169, both of which are within the DNA binding domain. However, only Ser45 and Ser131 were statistically dif-
ferentially regulated in response to either ETO or HU. While Ser131 was statistically elevated upon treatment
with ETO at 120 min, the fold change was marginal (1.03-fold), with similar fold change (1.05-fold) being
observed for this phosphosite in response to HU, albeit at a shorter 30 min time point. The RelA peptide contain-
ing pSer45 was unchanged upon ETO treatment, and was statistically down-regulated by 60 min exposure to HU,
again with low (1.05) fold change. Given that we were evaluating the total cellular pool of RelA, rather than spe-
cifically the nuclear portion where we would expect e.g. Ser45 phosphorylation to have a greater regulatory effect
[26], it is perhaps not surprising that the phosphopeptide changes quantified in this study were low.
A number of our findings of regulated phosphorylation site changes are in agreement with other published
studies. However, the overall fold change in phosphopeptide levels across this study were relatively small (max-
imally 1.7 fold), and speaks to the necessity to avoid, wherever possible, implementation of a fold-change
cut-off during this type of analysis. While ETO-regulated RelA bound phosphoproteins were primarily involved
in transcription, cell division and mitosis, and DSB repair (as might be expected), HU-mediated changes were
predominantly observed in proteins with functions in rRNA and mRNA processing, and translational initiation.
Where changes were observed, ETO predominantly resulted in elevated phosphopeptide levels, with a number
of the ETO-regulated phosphorylation sites identified having been reported previously to be modulated in
response to either IR or UV radiation. It was interesting to note that transcriptional regulation and DNA
damage repair proteins were enriched in those datasets with both elevated and reduced phosphopeptide levels,
suggesting coordinated regulation of these processes through different effectors in response to DSB. In addition
to the involvement in AMT/ATR signalling previously reported, potential substrates for which were much
more prevalent following ETO treatment that HU, kinase substrate prediction suggested roles for CDKs and
ERK1 (or their cognate phosphatases), in regulating RelA complexes in response to ETO. In contrast, levels of
the activation loop phosphopeptide in MAPK1/ERK2, traditionally thought to be a marker of kinase activity,
were elevated in response to HU, but not ETO, suggesting differential MAPK isoform signalling in response to
these two types of DNA damage. The prediction of substrates for p38α in the regulated phosphorylation sites
following cellular exposure to HU (but not ETO), also points to a potential HU-specific regulation of this stress
activated protein kinase. Finally, our data point to a role for 14-3-3ε binding propensity in facilitating the cellu-
lar response to HU, which may be a contributing factor in differentiating the pro-and anti-apopotic phenotypes
that are the result of prolonged cellular expose to these two types of DNA damaging agents, and we believe is
worthy of further investigation.
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